MX2020006884A - Metodos de purificacion de virus adenoasociado. - Google Patents

Metodos de purificacion de virus adenoasociado.

Info

Publication number
MX2020006884A
MX2020006884A MX2020006884A MX2020006884A MX2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A MX 2020006884 A MX2020006884 A MX 2020006884A
Authority
MX
Mexico
Prior art keywords
adeno
associated virus
purification methods
virus purification
aav
Prior art date
Application number
MX2020006884A
Other languages
English (en)
Spanish (es)
Inventor
Meinhard Hasslacher
Christian Fiedler
Jadranka Koehn
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020006884A publication Critical patent/MX2020006884A/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166Fluid composition conditioning, e.g. gradient
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424Elution mode
    • B01D15/426Specific type of solvent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/075Adenoviridae

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020006884A 2017-12-29 2018-12-27 Metodos de purificacion de virus adenoasociado. MX2020006884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611709P 2017-12-29 2017-12-29
PCT/US2018/067627 WO2019133677A1 (en) 2017-12-29 2018-12-27 Adeno-associated virus purification methods

Publications (1)

Publication Number Publication Date
MX2020006884A true MX2020006884A (es) 2020-10-01

Family

ID=67064154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006884A MX2020006884A (es) 2017-12-29 2018-12-27 Metodos de purificacion de virus adenoasociado.

Country Status (12)

Country Link
US (1) US11981934B2 (https=)
EP (1) EP3731863A4 (https=)
JP (2) JP7299896B2 (https=)
KR (1) KR20200106045A (https=)
CN (1) CN111655285B (https=)
AU (1) AU2018395254B2 (https=)
BR (1) BR112020013197A8 (https=)
CA (1) CA3084827A1 (https=)
IL (1) IL275533B2 (https=)
MX (1) MX2020006884A (https=)
SG (1) SG11202006232SA (https=)
WO (1) WO2019133677A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019299964A1 (en) * 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
EP3990031A4 (en) * 2019-06-28 2023-08-09 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
EP3868886A1 (en) * 2020-02-21 2021-08-25 Bia Separations D.O.O. A method for separation or depletion of empty aav capsids from full aav capsids
US20220033782A1 (en) * 2020-07-29 2022-02-03 Pall Corporation Adenovirus-associated viruses separation method
JP2023539163A (ja) * 2020-08-18 2023-09-13 ザルトリウス ビーアイエー セパレーションズ ディー.オー.オー. 宿主細胞dnaの金属アフィニティー抽出
JP2023548816A (ja) * 2020-11-03 2023-11-21 ファイザー・インク 陰イオン交換クロマトグラフィーによるaavベクターの精製方法
US20230416693A1 (en) * 2020-11-24 2023-12-28 Sartorius Bia Separations D.O.O. Improved washing methods for affinity chromatography
JP2024503234A (ja) * 2020-12-23 2024-01-25 ファイザー・インク 親和性クロマトグラフィーによるaavベクターの精製方法
EP4281552A4 (en) * 2021-01-21 2025-03-12 AskBio Inc. Method for purifying recombinant viral particles
WO2022222869A1 (zh) * 2021-04-19 2022-10-27 信念医药(香港)有限公司 重组腺相关病毒及其应用
CN114591921B (zh) * 2022-03-31 2024-08-02 上海勉亦生物科技有限公司 腺相关病毒的纯化方法和洗脱液
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法
US20230183659A1 (en) * 2021-10-29 2023-06-15 Homology Medicines, Inc. Methods and compositions for the purification of adeno-associated virus
CN114350622A (zh) * 2022-01-17 2022-04-15 苏州博腾生物制药有限公司 一种病毒纯化高效保护试剂及其应用
EP4490179A1 (en) 2022-03-07 2025-01-15 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
GB202206123D0 (en) * 2022-04-27 2022-06-08 Cytiva Bioprocess R & D Ab A pre-screening method and a method for separating adeno-associated virus capsids
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
WO2025027058A1 (en) * 2023-08-01 2025-02-06 Merck Patent Gmbh Polishing for aav particles using anion exchange chromatography with improved elution system
WO2025104341A1 (en) * 2023-11-16 2025-05-22 Sartorius Bia Separations D.O.O. Enhanced chromatographic separation of components in a mixture by employing decreasing gradient of complexing agent
WO2025207456A1 (en) * 2024-03-25 2025-10-02 Frontera Therapeutics, Inc. Methods for purification of adeno associated virus particles by anion exchange chromatography
WO2026077794A1 (en) * 2024-10-07 2026-04-16 Cytiva Us Llc Plasmid purification methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543363A (en) 1983-06-15 1985-09-24 Asahi Kasei Kogyo Kabushiki Kaisha Ion exchanger having hydroxyl groups bonded directly to backbone skeleton
SE9902133D0 (sv) 1999-06-06 1999-06-06 Amersham Pharm Biotech Ab A method for surface modification, a novel support matrix and the use of the matrix
GB9925432D0 (en) * 1999-10-27 1999-12-29 Univ London Virus preparation
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
HUE028341T2 (en) 2009-06-16 2016-12-28 Genzyme Corp Improved methods for purification of recombinant aav vectors
US20150275195A1 (en) * 2012-10-24 2015-10-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
CN104232687A (zh) * 2014-09-17 2014-12-24 许瑞安 一种重组腺相关病毒rAAV载体的分离纯化方法
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
KR20220100017A (ko) 2019-11-21 2022-07-14 이엠디 밀리포어 코포레이션 친수성 막

Also Published As

Publication number Publication date
KR20200106045A (ko) 2020-09-10
EP3731863A1 (en) 2020-11-04
JP2023089298A (ja) 2023-06-27
JP7299896B2 (ja) 2023-06-28
SG11202006232SA (en) 2020-07-29
RU2020124946A (ru) 2022-01-31
WO2019133677A1 (en) 2019-07-04
BR112020013197A2 (pt) 2021-02-17
AU2018395254A1 (en) 2020-06-25
CA3084827A1 (en) 2019-07-04
US11981934B2 (en) 2024-05-14
US20200332266A1 (en) 2020-10-22
EP3731863A4 (en) 2021-10-27
AU2018395254B2 (en) 2024-07-25
IL275533B1 (en) 2024-11-01
CN111655285A (zh) 2020-09-11
JP2021508484A (ja) 2021-03-11
BR112020013197A8 (pt) 2022-11-08
IL275533B2 (en) 2025-03-01
JP7531654B2 (ja) 2024-08-09
IL275533A (en) 2020-08-31
RU2020124946A3 (https=) 2022-02-08
CN111655285B (zh) 2025-02-25

Similar Documents

Publication Publication Date Title
MX2020006884A (es) Metodos de purificacion de virus adenoasociado.
AU2018260998A2 (en) Modulatory polynucleotides
EP4585229A3 (en) Means and method for preparing viral vectors and uses of same
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
PH12020500044A1 (en) Aav vector column purification methods
WO2019241535A3 (en) Anion exchange chromatography for recombinant aav production
EP4234688A3 (en) Adeno-associated virus purification methods
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
WO2016018740A8 (en) Purification platform for bispecific antibodies
MX2019013172A (es) Composiciones y metodos para tratar la enfermedad de huntington.
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
NZ737796A (en) Anti-tau antibodies and methods of use
WO2016012285A3 (en) Method
MY195391A (en) Column-Based Fully Scalable Raav Manufacturing Process
HK1244299A1 (zh) 治疗肌萎缩侧索硬化(als)的组合物和方法
AU2020299026A8 (en) Methods and AAV vectors for in vivo transduction
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
EP3533825A4 (en) ORGANIC-INORGANIC COMPOSITE FOR REINFORCING RUBBER, MANUFACTURING METHOD THEREFOR AND TIRE RUBBER COMPOSITION THEREFOR
EP4480577A3 (en) Structured elements and methods of use
EP3245218A4 (en) Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3880695A4 (en) ACTIVIN/BMP7 CHIMERAS: SUPERACTIVE SAB704 AND SAB715, AND THEIR RESPECTIVE NOGGINE-SENSITIZED VARIANTS, NAB704 AND NAB715; AND NAB204
IL284402A (en) A process for the production, isolation and purification of modified recombinant proteins
KUWATSUKA et al. Japanese-oriented call centers in Bangkok and agent of trade in service

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED